While investors chase semiconductor stocks, the healthcare sector has been sold down to historic lows relative to the S&P 500. Companies like Intuitive Surgical possess unique, valuable proprietary data that AI will leverage, turning these unloved firms into a compelling, long-term AI play.

A major investment opportunity lies in companies that use AI to extract the full information density from routine medical procedures. For example, analyzing a mammogram not just for cancer but also for arterial calcification, which indicates cardiovascular risk—a critical learning that is currently often discarded.

Fields like dermatology, once considered too operationally expensive and services-heavy for venture scale, are now attractive investment areas. AI enables scalable solutions for remote diagnostics, personalized treatment plans, and progress tracking, reducing capital expenditure and unlocking a massive consumer spend category.

While capital chases obvious AI plays, significant opportunities exist in overlooked sectors. For example, life science tools are poised to benefit from two major trends: AI-driven drug discovery and the reshoring of pharmaceutical manufacturing. This makes the space a potential "AI winner" hiding in plain sight.

The AI investment case might be inverted. While tech firms spend trillions on infrastructure with uncertain returns, traditional sector companies (industrials, healthcare) can leverage powerful AI services for a fraction of the cost. They capture a massive 'value gap,' gaining productivity without the huge capital outlay.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

Past tech waves like the internet were marginal, "back office" improvements for biotech. AI is a computational shift that will transform the core scientific process, making it the first truly disruptive tech revolution for the industry.

In the past, AI drug discovery startups often had to build their own drug pipeline to succeed. Now, a market shift is occurring where large pharmaceutical companies are actively acquiring or licensing specialized AI models and platforms, validating the business model of being a pure AI provider to the industry.

Many diseases have well-understood genetic causes but lack effective treatments. Genesis CEO Evan Feinberg argues this makes drug discovery the most impactful area for AI, as it directly addresses the bottleneck of creating selective therapies for known targets where no medicine currently exists.